295 related articles for article (PubMed ID: 21179588)
1. SRp20 is a proto-oncogene critical for cell proliferation and tumor induction and maintenance.
Jia R; Li C; McCoy JP; Deng CX; Zheng ZM
Int J Biol Sci; 2010 Dec; 6(7):806-26. PubMed ID: 21179588
[TBL] [Abstract][Full Text] [Related]
2. Knockdown of splicing factor SRp20 causes apoptosis in ovarian cancer cells and its expression is associated with malignancy of epithelial ovarian cancer.
He X; Arslan AD; Pool MD; Ho TT; Darcy KM; Coon JS; Beck WT
Oncogene; 2011 Jan; 30(3):356-65. PubMed ID: 20856201
[TBL] [Abstract][Full Text] [Related]
3. Peroxiredoxin II promotes hepatic tumorigenesis through cooperation with Ras/Forkhead box M1 signaling pathway.
Park YH; Kim SU; Kwon TH; Kim JM; Song IS; Shin HJ; Lee BK; Bang DH; Lee SJ; Lee DS; Chang KT; Kim BY; Yu DY
Oncogene; 2016 Jul; 35(27):3503-13. PubMed ID: 26500057
[TBL] [Abstract][Full Text] [Related]
4. Regulation of CD44E by DARPP-32-dependent activation of SRp20 splicing factor in gastric tumorigenesis.
Zhu S; Chen Z; Katsha A; Hong J; Belkhiri A; El-Rifai W
Oncogene; 2016 Apr; 35(14):1847-56. PubMed ID: 26119931
[TBL] [Abstract][Full Text] [Related]
5. Alternative splicing of the multidrug resistance protein 1/ATP binding cassette transporter subfamily gene in ovarian cancer creates functional splice variants and is associated with increased expression of the splicing factors PTB and SRp20.
He X; Ee PL; Coon JS; Beck WT
Clin Cancer Res; 2004 Jul; 10(14):4652-60. PubMed ID: 15269137
[TBL] [Abstract][Full Text] [Related]
6. Regulated expression and RNA processing of transcripts from the Srp20 splicing factor gene during the cell cycle.
Jumaa H; Guénet JL; Nielsen PJ
Mol Cell Biol; 1997 Jun; 17(6):3116-24. PubMed ID: 9154810
[TBL] [Abstract][Full Text] [Related]
7. SRp20: A potential therapeutic target for human tumors.
Wang H; Jiang Y
Pathol Res Pract; 2021 Aug; 224():153444. PubMed ID: 34126370
[TBL] [Abstract][Full Text] [Related]
8. Alterations in expression pattern of splicing factors in epithelial ovarian cancer and its clinical impact.
Iborra S; Hirschfeld M; Jaeger M; Zur Hausen A; Braicu I; Sehouli J; Gitsch G; Stickeler E
Int J Gynecol Cancer; 2013 Jul; 23(6):990-6. PubMed ID: 23748175
[TBL] [Abstract][Full Text] [Related]
9. Splicing factor SRP20 is a novel partner of BCL6 in a t(3;6)(q27;p21) translocation in transformed follicular lymphoma.
Chen W; Itoyama T; Chaganti RS
Genes Chromosomes Cancer; 2001 Nov; 32(3):281-4. PubMed ID: 11579468
[TBL] [Abstract][Full Text] [Related]
10. Multiple effects of digoxin on subsets of cancer-associated genes through the alternative splicing pathway.
Lu GY; Liu ST; Huang SM; Chang YL; Lin WS
Biochimie; 2014 Nov; 106():131-9. PubMed ID: 25193633
[TBL] [Abstract][Full Text] [Related]
11. The gene encoding the splicing factor SF2/ASF is a proto-oncogene.
Karni R; de Stanchina E; Lowe SW; Sinha R; Mu D; Krainer AR
Nat Struct Mol Biol; 2007 Mar; 14(3):185-93. PubMed ID: 17310252
[TBL] [Abstract][Full Text] [Related]
12. Protein cross-talk in CD133+ colon cancer cells indicates activation of the Wnt pathway and upregulation of SRp20 that is potentially involved in tumorigenicity.
Corbo C; Orrù S; Gemei M; Noto RD; Mirabelli P; Imperlini E; Ruoppolo M; Vecchio LD; Salvatore F
Proteomics; 2012 Jun; 12(12):2045-59. PubMed ID: 22623141
[TBL] [Abstract][Full Text] [Related]
13. Reciprocal activation between PLK1 and Stat3 contributes to survival and proliferation of esophageal cancer cells.
Zhang Y; Du XL; Wang CJ; Lin DC; Ruan X; Feng YB; Huo YQ; Peng H; Cui JL; Zhang TT; Wang YQ; Zhang H; Zhan QM; Wang MR
Gastroenterology; 2012 Mar; 142(3):521-530.e3. PubMed ID: 22108192
[TBL] [Abstract][Full Text] [Related]
14. FOXM1 (Forkhead box M1) in tumorigenesis: overexpression in human cancer, implication in tumorigenesis, oncogenic functions, tumor-suppressive properties, and target of anticancer therapy.
Wierstra I
Adv Cancer Res; 2013; 119():191-419. PubMed ID: 23870513
[TBL] [Abstract][Full Text] [Related]
15. Overexpression of GOLPH3 promotes proliferation and tumorigenicity in breast cancer via suppression of the FOXO1 transcription factor.
Zeng Z; Lin H; Zhao X; Liu G; Wang X; Xu R; Chen K; Li J; Song L
Clin Cancer Res; 2012 Aug; 18(15):4059-69. PubMed ID: 22675169
[TBL] [Abstract][Full Text] [Related]
16. The beta-catenin/TCF4 pathway modifies alternative splicing through modulation of SRp20 expression.
Gonçalves V; Matos P; Jordan P
RNA; 2008 Dec; 14(12):2538-49. PubMed ID: 18952824
[TBL] [Abstract][Full Text] [Related]
17. Proteomic-based analysis of nuclear signaling: PLCbeta1 affects the expression of the splicing factor SRp20 in Friend erythroleukemia cells.
Bavelloni A; Faenza I; Cioffi G; Piazzi M; Parisi D; Matic I; Maraldi NM; Cocco L
Proteomics; 2006 Nov; 6(21):5725-34. PubMed ID: 17022104
[TBL] [Abstract][Full Text] [Related]
18. TSGΔ154-1054 splice variant increases TSG101 oncogenicity by inhibiting its E3-ligase-mediated proteasomal degradation.
Chua HH; Huang CS; Weng PL; Yeh TH
Oncotarget; 2016 Feb; 7(7):8240-52. PubMed ID: 26811492
[TBL] [Abstract][Full Text] [Related]
19. Cell cycle-dependent expression of p42.3 promotes mitotic progression in malignant transformed cells.
Mao L; Sun W; Li W; Cui J; Zhang J; Xing R; Lu Y
Mol Carcinog; 2014 May; 53(5):337-48. PubMed ID: 23192843
[TBL] [Abstract][Full Text] [Related]
20. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients.
Tassi RA; Todeschini P; Siegel ER; Calza S; Cappella P; Ardighieri L; Cadei M; Bugatti M; Romani C; Bandiera E; Zanotti L; Tassone L; Guarino D; Santonocito C; Capoluongo ED; Beltrame L; Erba E; Marchini S; D'Incalci M; Donzelli C; Santin AD; Pecorelli S; Sartori E; Bignotti E; Odicino F; Ravaggi A
J Exp Clin Cancer Res; 2017 May; 36(1):63. PubMed ID: 28482906
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
